tetano
Editor, Senior Moderator
Pancreas
. 2021 Oct 1;50(9):1310-1313.
doi: 10.1097/MPA.0000000000001922.
Analysis of Outcomes in COVID-19 Patients With Varying Degrees of Hyperlipasemia
Petros C Benias[SUP] 1 [/SUP], Sumant Inamdar[SUP] 2 [/SUP], Diana Wee[SUP] 3 [/SUP], Yan Liu[SUP] 4 [/SUP], Jonathan M Buscaglia[SUP] 5 [/SUP], Sanjaya K Satapathy, Arvind J Trindade, Northwell COVID-19 Research Consortium
Affiliations
Abstract
Objectives: Coronavirus disease 2019 (COVID-19) patients may have varying degrees of hyperlipasemia. The aim was to compare outcomes among different levels of hyperlipasemia in patients with COVID-19.
Methods: This is a retrospective study examining outcomes among hospitalized COVID-19 patients with a lipase <3× upper limit of normal (ULN), asymptomatic hyperlipasemia (>3× ULN), secondary pancreatitis (typical respiratory COVID-19 symptoms and found to have pancreatitis), and primary pancreatitis (presenting with pancreatitis).
Results: Of 11,883 patients admitted with COVID-19, 1560 patients were included: 1155 patients had normal serum lipase (control group), 270 had elevated lipase <3× ULN, 46 patients had asymptomatic hyperlipasemia with lipase >3× ULN, 57 patients had secondary pancreatitis, and 32 patients had primary pancreatitis. On adjusted multivariate analysis, the elevated lipase <3× ULN and asymptomatic hyperlipasemia groups had worse outcomes with higher mortality (odds ratio [OR], 1.6 [95% confidence interval [CI], 1.2-2.2) and 1.1 [95% CI, 0.5-2.3], respectively), higher need for mechanical ventilation (OR, 2.8 [95% CI, 1.2-2.1] and 2.8 [95% CI, 1.5-5.2], respectively), and longer length of stay (OR, 1.5 [95% CI, 1.1-2.0] and 3.16 [95% CI, 1.5-6.5], respectively).
Conclusions: Patients with COVID-19 with elevated lipase <3× ULN and asymptomatic hyperlipasemia have generally worse outcomes than those with pancreatitis.
. 2021 Oct 1;50(9):1310-1313.
doi: 10.1097/MPA.0000000000001922.
Analysis of Outcomes in COVID-19 Patients With Varying Degrees of Hyperlipasemia
Petros C Benias[SUP] 1 [/SUP], Sumant Inamdar[SUP] 2 [/SUP], Diana Wee[SUP] 3 [/SUP], Yan Liu[SUP] 4 [/SUP], Jonathan M Buscaglia[SUP] 5 [/SUP], Sanjaya K Satapathy, Arvind J Trindade, Northwell COVID-19 Research Consortium
Affiliations
- PMID: 34860817
- DOI: 10.1097/MPA.0000000000001922
Abstract
Objectives: Coronavirus disease 2019 (COVID-19) patients may have varying degrees of hyperlipasemia. The aim was to compare outcomes among different levels of hyperlipasemia in patients with COVID-19.
Methods: This is a retrospective study examining outcomes among hospitalized COVID-19 patients with a lipase <3× upper limit of normal (ULN), asymptomatic hyperlipasemia (>3× ULN), secondary pancreatitis (typical respiratory COVID-19 symptoms and found to have pancreatitis), and primary pancreatitis (presenting with pancreatitis).
Results: Of 11,883 patients admitted with COVID-19, 1560 patients were included: 1155 patients had normal serum lipase (control group), 270 had elevated lipase <3× ULN, 46 patients had asymptomatic hyperlipasemia with lipase >3× ULN, 57 patients had secondary pancreatitis, and 32 patients had primary pancreatitis. On adjusted multivariate analysis, the elevated lipase <3× ULN and asymptomatic hyperlipasemia groups had worse outcomes with higher mortality (odds ratio [OR], 1.6 [95% confidence interval [CI], 1.2-2.2) and 1.1 [95% CI, 0.5-2.3], respectively), higher need for mechanical ventilation (OR, 2.8 [95% CI, 1.2-2.1] and 2.8 [95% CI, 1.5-5.2], respectively), and longer length of stay (OR, 1.5 [95% CI, 1.1-2.0] and 3.16 [95% CI, 1.5-6.5], respectively).
Conclusions: Patients with COVID-19 with elevated lipase <3× ULN and asymptomatic hyperlipasemia have generally worse outcomes than those with pancreatitis.